Vaccine development: progression from target antigen to product.
Ellis
R W
RW
Cellular and Molecular Biology, Merck Sharp & Dohme Research Laboratories, West Point, PA 19486.
D000942:Antigens, Bacterial / Q000737:chemistry* / Q000276:immunology; D001425:Bacterial Outer Membrane Proteins / Q000737:chemistry* / Q000592:standards; D001428:Bacterial Vaccines / Q000737:chemistry* / Q000592:standards; D015195:Drug Design; D018073:Haemophilus Vaccines; D006193:Haemophilus influenzae / Q000737:chemistry* / Q000276:immunology*; D006801:Humans; D011135:Polysaccharides, Bacterial / Q000737:chemistry*
D000942:Antigens, Bacterial; D001425:Bacterial Outer Membrane Proteins; D001428:Bacterial Vaccines; D018073:Haemophilus Vaccines; C061964:Haemophilus influenzae-type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine; D011135:Polysaccharides, Bacterial